Welcome
Support Centre
14 March 2010 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   UKCTG  |   links  |   information  |   press
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes

[ Print-friendly version ]
Physical Activity during Cancer Treatment (PACT) study
ISRCTN ISRCTN43801571
ClinicalTrials.gov identifier
Public title Physical Activity during Cancer Treatment (PACT) study
Scientific title A randomised clinical trial of physical exercise during cancer treatment: the PACT-study
Acronym PACT
Serial number at source N/A
Study hypothesis We hypothesise that early physical exercise by reducing complaints of fatigue will lead to a reduction in sick leave and production losses. Altogether, we expect that physical exercise during cancer treatment will be cost-effective.
Ethics approval Medical Ethics Committee of the University Medical Centre Utrecht approved on the 27th February 2008 (ref: 07/271/O)
Study design Multicentre pragmatic randomised controlled trial
Countries of recruitment Netherlands
Disease/condition/study domain Breast cancer/colon cancer
Participants - inclusion criteria 1. Recently diagnosed with breast or colon cancer (stage M0): histological diagnosis of cancer less than six (breast cancer) or ten (colon cancer) weeks ago
2. Treated with chemotherapy
3. Aged 25 - 75 years, either sex
4. Able to read and understand the Dutch language
5. Karnovsky Performance Status of 60 or higher
6. Able to walk 100 metres or more
Participants - exclusion criteria 1. Treated for cancer in the past five years (except basal skin cancer)
2. Contraindications for physical activity (Revised Physical Activity Readiness Questionnaire)
Anticipated start date 01/01/2010
Anticipated end date 31/12/2012
Status of trial Ongoing
Patient information material Not available in web format, please use the contact details below to request a patient information sheet
Target number of participants 300
Interventions During an intake, patients will be included, baseline measurements will be taken and patients will be randomly allocated to the intervention or control group. Participants assigned to the intervention group will receive usual care in combination with an 18-week supervised group exercise program. They will be encouraged to attend the exercise program two times a week supervised by a physiotherapist.

Participants who will be assigned to the control group will receive usual care, i.e., no exercise intervention.

We will assess the short term as well as the long term effects. Short term effects will be measured 18 weeks after inclusion (at the end of the program) and long term effects will be measured 9 months after inclusion.
Primary outcome measure(s) Measured at baseline, 18 weeks and 9 months:
1. Fatigue
2. Health service utilisation and sick leave
Secondary outcome measure(s) Measured at baseline, 18 weeks and 9 months:
1. Health related quality of life
2. Anxiety and depression
3. Physical fitness
4. Body composition
5. Cognitive behavioural aspects
6. Physical activity level
Sources of funding The Netherlands Organisation for Health Research and Development (ZonMw) (Netherlands) (ref: 171002202)
Trial website
Publications
Contact name Prof  Petra  Peeters
  Address Universitair Medisch Centrum Utrecht
Julius Center
PO Box 85500
  City/town Utrecht
  Zip/Postcode 3508 GA
  Country Netherlands
  Email p.h.m.peeters@umcutrecht.nl
Sponsor The Netherlands Organisation for Health Research and Development (ZonMw) (Netherlands)
  Address Laan van Nieuw Oost Indië 334
  City/town Den Haag
  Zip/Postcode 2593 CE
  Country Netherlands
  Email rossum@zonmw.nl
  Sponsor website: http://www.zonmw.nl/
Date applied 17/12/2009
Last edited 26/01/2010
Date ISRCTN assigned 26/01/2010
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© ISRCTN


BioMed Central